TOKYO, June 16, 2021  - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that Astellas and Cheplapharm Arzneimittel GmbH (“Cheplapharm”) have enterd into an Asset Purchase Agreement, under which Astellas will transfer the Products Rights for five legacy products (the “Products”) in certain countries of Europe, Russia, Commonwealth of Independent States (CIS)1 and Asia.

Once the transaction closes, Cheplapharm will take over the Products Rights from Astellas and sell them in certain countries of Europe, Russia, CIS and Asia. Astellas will work closely with Cheplapharm to enable a smooth transition.

(1) Purpose of Asset Purchase Agreement
The agreement is a part of Astellas’ ongoing efforts to improve the quality and efficiency of operations so as to accommodate the rapidly changing business environment and achieve sustainable growth. Astellas will continue to strengthen our business presence in Europe, Russia, CIS, and Asia through optimization of resource allocation.

(2) Financial Terms of Asset Purchase Agreement
€95 million 

(3) Schedule of Asset Purchase Agreement
June 15, 2021: Signing of the Asset Purchase Agreement
September 2021 or later: Closing of the transaction(tentative)

After closing of the transaction, the Products Rights for the Products will be transferred in each country.

(4) List of the Products

Products Name Indication
FLEMOXIN® Acute respiratory infections, Helicobacter pylori associated diseases, such as gastritis and gastric ulcer, urogenital infections and others
DE-NOL® Gastro protector with antibacterial effect on H. pylori 
SUPRAX® Chronic and recurrent respiratory infections with the highest activity towards H. influenzae. Infections caused by susceptible bacteria, such as urinary tract infections and others, e.g. skin, secondary infection in trauma, burn or surgical wound, cholangitis
UNIDOX® Infections, such as mild community acquired pneumonia, acute exacerbations of chronic bronchitis, lymphogranuloma venereum, acne vulgaris, chlamydia trachomatis infections, prostatitis, cervicitis and pelvic inflammatory diseases
ORBENINE® Infections caused by gram-positive organisms (except MRSA and MRSE), including infections caused by beta-lactamase producing staphylococci

 

(5) Sales of the Products
€81.5 million(fiscal year ended March 31, 2021)

Astellas has already reflected the impact from this transaction in its financial forecast of the current fiscal year ending March 31, 2022.

 

Click below for a copy of the full press release